A prescription event monitoring study on the utility of garenoxacin, a newer fluoroquinolone in India

Anoop Hajare, Amandeep Gupta, Saiprasad Patil, K Krishnaprasad, Amit Bhargava
Department of Medical Services, Glenmark Pharmaceuticals Ltd., Mumbai, Maharashtra, India

Abstract

Background: Prescription event monitoring (PEM) study is conducted worldwide. The main objective of such study is to monitor the adverse events when a drug is being prescribed in “real life clinical” settings. PEM studies are being looked upon as an essential observational tool of postmarketing surveillance. Garenoxacin, a newer fluoroquinolone offers an excellent spectrum of antimicrobial coverage, which includes Gram-positive, Gram-negative, anaerobes and atypical microorganism. This broad spectrum of activity is attributed to its unique structure. Aim: The aim was to assess the safety profile of garenoxacin in Indian settings. Materials and Methods: A total of 400 doctors across the country participated in the study. Data from 12,498 patients was obtained. Monitoring of each patient was done for any adverse events. Results: As an initial line of therapy garenoxacin was preferred in majority of cases of community-acquired pneumonia (CAP) and acute exacerbations of chronic bronchitis. Adverse events were reported in 159 patients which included 0.5% cases with nausea/vomiting, 0.1% cases with diarrhea. Central nervous system side-effects like drowsiness or dizziness was reported in 0.02% of the cases. All the adverse events were of mild to moderate severity and did not require hospitalization. Conclusion: Garenoxacin a novel desfluoroquinolone appears to be an ideal antimicrobial agent for the treatment of various respiratory tract infections including CAP. With superior safety profile, excellent antimicrobial coverage and a convenient once a day dosing garenoxacin appears to improve the patient compliance.

Key words: Adverse events, garenoxacin, prescription event monitoring, respiratory tract infections, safety
Submission: 09-08-2014 Accepted: 14-12-2014

Introduction

Community-acquired respiratory tract infections (RTIs) represent one of the most common and important infections that are treated by clinicians.[1] It is becoming increasingly difficult to treat RTIs and otorhinolaryngological infections owing to the increase in resistant Gram-positive and Gram-negative bacteria.[2-4]

Depending on local prevalence, empirical antibacterial therapy is often directed against Streptococcus pneumoniae (including penicillin resistant S. pneumoniae [PRSP]), Haemophilus influenzae, Moraxella catarrhalis, methicillin-susceptible Streptococcus aureus, “atypical pathogens” (Mycoplasma, chlamydia and Legionella spp.) and under appropriate clinical settings, Gram-negative bacilli and anaerobes.

Garenoxacin with a broad spectrum of coverage appears to be an ideal agent in the treatment of such infections.[5]

Materials and Methods

A prescription event monitoring (PEM) study was conducted between July 15, 2013 and September 15, 2013 with 400 doctors across India. A PEM study booklet, containing a letter of introduction to the doctor, a PEM report form, and a study flow chart with a patient log sheet, was sent to these prescribing doctors, requesting information on any “events” that occurred during the observation period of the prescription. From each doctor, observations from
his/her patients were requested for whom garenoxacin 400 mg (200 mg, 2 tablets stat once a day) was prescribed for 5–14 days depending upon the severity of the infection and as per the details of the prescribing information sheet provided.

The term “events,” in PEM study, is defined as, including any new diagnosis, any reason for referral to a consultant or admission to hospital, any unexpected deterioration (or improvement) in their chest disease or a concurrent illness, any suspected drug reaction, any alteration of clinical importance in laboratory values or any other complaint that was considered of sufficient importance. The PEM report form also included additional questions like the indication for which garenoxacin was prescribed, duration of treatment, concurrent medical history (whether the patient had a history of diabetes mellitus, HIV and tuberculosis) and the final outcome of the disease. During the observation period, each patient was observed for any “events” that may arise thereof that noted in PEM report form and notified immediately to sponsor pharmacovigilance center in case of serious adverse events including death, disability, hospitalization or congenital anomaly. At the end of the observation period, the PEM booklets were collected. Based on the safety profile or observations with the drug, additional follow-up was done with the prescribing doctors for confirmation and causality assessment based on the pharmacological properties, concurrent disease or drug use.

Descriptive statistics was used to present the data.

**RESULTS**

**Baseline demographics**

Data from 12,498 patients was available at the end of the observation period. Amongst the patients who were prescribed garenoxacin, 70.3% patients were males and 29.7% patients were females with a mean age of 47.9 years. Patients were initiated on garenoxacin therapy for various community-acquired infections based on the clinical suspicion of bacterial etiology especially in terms of presenting symptoms with or without the associated laboratory findings or concomitant risk factors and/or medical history [Figure 1].

The baseline demographic parameters of the study representing gender, age, medical history and antibiotic use amongst the patients are shown in Table 1.

Garenoxacin was clinically evaluated for its utility in community-acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB), upper RTI (pharyngitis/tonsilitis), sinusitis, skin and skin structure infections (SSSTIs), and urinary tract infection (UTI) as shown in Figure 2.

Garenoxacin was prescribed at a dose of 400 mg OD (200 mg × 2 tablets) with the duration varying from 5 to 14 days depending upon the severity of condition, especially for lower RTIs (LRTIs), including CAP. Garenoxacin was preferred as first-line therapy among patients with CAP (84.6%) or AECB (85.2%) usually for 5–7 days [Figures 3 and 4].

In these cases of LRTIs, garenoxacin was usually prescribed for 5–7 days. Amongst the 3921 patients with AECB, garenoxacin was prescribed for 77.3% patients for 5 days, 19.9% patients for 7 days and 2.7% patients for 14 days.

**Clinical assessment**

Clinical response was judged by subjective assessment for control of presenting symptoms. Data records were available for 11,698 patients with 8303 (70.9%), 3322 (20.4%) demonstrating cure and improvement rate respectively. Two failure cases were noted during the course of the observation period that was managed symptomatically in the outpatient setting without further hospitalization. Cure, improvement and failure was suggested by the treating physician as:

**Cure**

Complete disappearance of clinical signs and symptoms within the treatment period.

**Improvement**

Subsidence of clinical signs and symptoms (50%) but with incomplete resolution.

**Failure**

Unchanged or worsening of baseline clinical signs and symptoms.

**Event analyses**

159 patients reported adverse drug reactions that were
mainly mild and transient. The side effects noted were mainly gastrointestinal disturbances in form of diarrhea, nausea and/or vomiting and dysgeusia [Figure 5].

**Discussion**

Community-acquired pneumonia appears to be a global concern with a significant morbidity and mortality. In Europe, it affects approximately 1.6–10.6/1,000 adult populations every year.[6] Guidelines commonly adopted by the physicians for the treatment of CAP are the Infectious Disease Society of America (IDSA)/American Thoracic Society. The current IDSA guidelines of 2012[7] suggests the use of respiratory fluoroquinolones such as moxifloxacin, gemifloxacin, and levofloxacin in the treatment of CAP. The aim of the therapy should be to use antibiotics, which can target common pathogens at lower minimum inhibitory concentrations (MICs).

Surveillance studies conducted worldwide have shown rising MICs for amoxicillin–clavulanate combinations with ≈ 4–7% strains demonstrating MICs of 4 mg/L.[8,9] These strains are not covered with classical dosage administration of 625 mg for the combination given 3 times a day and require further higher dose supplementation.[6] Ho et al.[10] demonstrated fluoroquinolone resistance emerging in South East Asian countries including Hong Kong where the resistance rates have been 13.3% and 8.9% for levofloxacin and moxifloxacin respectively. Similarly in Asian population, the high prevalence of atypical pathogens (23.5%) amongst CAP patients presents a unique challenge in empirical management.[11] However the high rates of macrolide-resistant *Mycoplasma pneumoniae* reported in China (>90%) and Japan (87.1%)[12,13] have only increased.
Hajare, et al.: Prescription event monitoring study for garenoxacin in India

our efforts in quest for a safe yet effective antibiotic against community-acquired infections.

**Streptococcus pneumonia**

Worldwide there has been a steady rise in the prevalence of PRSP strains that are resistant to conventional dosages of amoxicillin – clavulinate and levofoxacin.

**Hemophilus influenza**

In elderly individuals, particularly those with underlying lung disease *H. influenza* can cause severe pneumonia. The development of β-lactamase negative ampicillin resistant strains (BLNAR) has been considered as an important advance in the evolution of these organism species since there is associated alteration of penicillin binding protein binding site. Prevalence of BLNAR among *H. influenza* has been increasing in various countries, including Asia (18.2%).[18,19]

**Atypical pathogens**

Similarly in Asian population the high prevalence of atypical pathogens amongst CAP patients presents a unique challenge in empirical management.

Prescription event monitoring study is a well-established, noninterventional, observational tool of postmarketing surveillance (PMS) when giving or prescribing drugs in “real life” clinical practice, on a national level, including patients with comorbidities and concomitant medications.[19] A PEM was therefore conducted, to better understand the health outcome or safety profile of garenoxacin when administered in “real world” out-patient clinical settings of India. Importantly, in a PEM study, there is no need for the prescribing doctor to give an opinion about whether an “event” might have been caused by the drug. At the end of the observation period, this data would be submitted for subsequent analyses.

Garenoxacin is a newly developed quinolone in Japan that was further researched and developed by Toyoma Ltd., in collaboration with Bristol Meyers Squibb, USA. Drug Controller General of India (DCGI) has approved the use of garenoxacin on 07/06/2013 for the treatment of bacterial RTIs with permission no. MF-131/13 in form 46 under Drugs and Cosmetic Acts and Rules thereunder.[16] It was subsequently launched in India by Glenmark Pharmaceuticals Ltd.

Garenoxacin has been demonstrated to have excellent pharmacokinetics/pharmacodynamics (PK/PD) profile due to structural modification of the quinolone at 6th, 7th and 8th positions. This unique structure activity relationship offers one of the lowest MICs against respiratory pathogens coupled with complimentary lowering in potential for resistance development as reflected by low mutant prevention concentrations.[17]

Garenoxacin is therefore a welcome addition to the therapeutic armamentarium of the clinicians while treating some of the community-acquired RTIs, especially in “empirical” settings.

Under the clinical research program involving international collaborators, nearly 20 Phase I/II/III/IV trials with approximately 10,000 patients has been conducted with some of them published as late as in 2011.[18,19]

Garenoxacin mesylate has been well-tolerated in above clinical trials with its true character revealed in “real world clinical settings” or PMS studies.

In a clinical review of literature by Takagi et al.[18] involving clinical trials conducted between 2001 and 2004, garenoxacin was found to be safe and effective. Drug related adverse events were observed in 12.7% cases. The common adverse events were diarrhea (2.4%), nausea (1%) and headache (1%). All the events were of mild to moderate severity and did not require discontinuation of therapy.

However in a PMS study conducted by Hori and Maki[19] in “real-world outpatient settings,” safety records from 6412 patients were accessed. Garenoxacin use reported negligible incidence of gastrointestinal disturbances including diarrhea (0.5%), dizziness (0.05%), somnolence (0.06%) or hypotension (0.05%) thus offering a unique safety profile that is unparalleled among fluoroquinolones or β-lactams.

The current study once again demonstrated the superior safety profile of garenoxacin with negligible incidence of gastrointestinal, central nervous system and cardiovascular side-effects. Diarrhea was noted in 0.1% of the patients that is similar with the earlier reported incidence of 0.5% by Hori and Maki[19]. None of the patients developed any serious cardiovascular reactions including QTc prolongation or torsades pointes at the end of the observation period.

Two failure cases were noted during the course of the observation period that was managed symptomatically with injectable β-lactam or ceftriaxone/tazobactam therapy that was administered in the outpatient setting without further need for hospitalization.

**Conclusion**

Since the introduction of garenoxacin in India for the first time, this PEM study demonstrated the excellent tolerability and utility of the drug in varied clinical conditions, especially in community-acquired infections when administered as empirical choice. Garenoxacin with its superior yet differentiated PD and PK profile involving low MICs with high target site tissue
concentrations definitely finds a merit for further evaluation in other uncomplicated clinical conditions, including SSSTIs, UTIs, gastrointestinal infections and typhoid.

References

1. Stratton CW. Bacterial pneumonias – An overview with emphasis on pathogenesis, diagnosis, and treatment. Heart Lung 1986;15:226-44.
2. File TM Jr. *Streptococcus pneumoniae* and community-acquired pneumonia: A cause for concern. Am J Med 2004;117 Suppl 3A: 395-50.
3. Jain SK, Tunkel DE, Bishai WR. Management of acute rhinosinusitis, bronchitis syndromes, and acute otitis media. Adv Stud Med 2005;5:344-50.
4. Johnson DM, Stilwell MG, Fritsche TR, Jones RN. Emergence of multidrug-resistant *Streptococcus pneumoniae*: Report from the SENTRY Antimicrobial Surveillance Program (1999-2003). Diagn Microbiol Infect Dis 2006;56:69-74.
5. Fung-Tomc JC, Minassian B, Kolek B, Huczko E, Aleksunes L, Stickle T, et al. Antibacterial spectrum of a novel des-fluoro (6) quinolone, BMS-284756. Antimicrob Agents Chemother 2000;44:3351-6.
6. Liapikou A, Torres A. Current treatment of community-acquired pneumonia. Expert Opin Pharmacother 2013;14:1319-32.
7. Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG, et al. 2012 infectious diseases society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2012;54:e132-73.
8. Felmingham D, Reinert RR, Hirakata Y, Rodloff A. Increasing prevalence of antimicrobial resistance among isolates of *Streptococcus pneumoniae* from the PROTEKT surveillance study, and comparative *in vitro* activity of the ketolide, telithromycin. J Antimicrob Chemother 2002;50 Suppl S1:25-37.
9. White AR. Augmentin® (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: A review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother 2004;53 Suppl S1:i3-20.
10. Ho PL, Tse WS, Tsang KW, Kwok TK, Ng TK, Cheng VC, et al. Risk factors for acquisition of levofloxacin-resistant *Streptococcus pneumoniae*: A case-control study. Clin Infect Dis 2001;32:701-7.
11. Ngeow YE, Suwanjutha S, Chantarojanasiri T, Wang F, Saniel M, Alejandria M, et al. An Asian study on the prevalence of atypical respiratory pathogens in community-acquired pneumonia. Int J Infect Dis 2005;9:144-53.
12. Okada T, Morozumi M, Tajima T, Hasegawa M, Sakata H, Ohnari S, et al. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant *Mycoplasma pneumoniae* infection in a 2011 outbreak among Japanese children. Clin Infect Dis 2012;55:1642-9.
13. Cao B, Zhao CJ, Yin YD, Zhao F, Song SF, Bai L, et al. High prevalence of macrolide resistance in *Mycoplasma pneumoniae* isolates from adult and adolescent patients with respiratory tract infection in China. Clin Infect Dis 2010;51:189-94.
14. Lulitanond A, Chanawong A, Pienthaweechai K, Sribenjalux P, Tavichakorntrakool R, Wilailuckana C, et al. Prevalence of β-lactamase-negative ampicillin-resistant *Haemophilus influenzae* isolated from patients of a teaching hospital in Thailand. Jpn J Infect Dis 2012;65:122-5.
15. Mann RD. Prescription-event monitoring – Recent progress and future horizons. Br J Clin Pharmacol 1998;46:195-201.
16. Available from: http://www.cdsco.nic.in/forms/list.aspx?lid=11. [Last accessed on 2015 Apr 23].
17. Andersson MI, MacGowan AP. Development of the quinolones. J Antimicrob Chemother 2003;51 Suppl 1:i-11.
18. Takagi H, Tanaka K, Tsuda H, Kobayashi H. Clinical studies of garenoxacin. J Int Antimicrob Agents 2008;32:468-74.
19. Hori S, Maki N. Survey on the usage results of Garenoxacin tablets. Post marketing surveillance report. Jpn J Chemother 2011;59:495-511.

How to cite this article: Hajare A, Gupta A, Patil S, Krishnaprasad K, Bhargava A. A prescription event monitoring study on the utility of garenoxacin, a newer fluoroquinolone in India. Int J App Basic Med Res 2015;5:87-91.

Source of Support: Nil. Conflict of Interest: None declared.